(S)-4-(4-((3-hydroxyquinuclidin-3-yl)ethynyl)phenoxy)-N-(1-methylpiperidin-4-yl)benzamide

ID: ALA1940308

Chembl Id: CHEMBL1940308

PubChem CID: 57394711

Max Phase: Preclinical

Molecular Formula: C28H33N3O3

Molecular Weight: 459.59

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CN1CCC(NC(=O)c2ccc(Oc3ccc(C#C[C@]4(O)CN5CCC4CC5)cc3)cc2)CC1

Standard InChI:  InChI=1S/C28H33N3O3/c1-30-16-13-24(14-17-30)29-27(32)22-4-8-26(9-5-22)34-25-6-2-21(3-7-25)10-15-28(33)20-31-18-11-23(28)12-19-31/h2-9,23-24,33H,11-14,16-20H2,1H3,(H,29,32)/t28-/m0/s1

Standard InChI Key:  RMPYEISUTHEMLW-NDEPHWFRSA-N

Alternative Forms

1. Parent:

   

   ALA1940308

   4-[4-[2-[(3S)-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]ethynyl]phenoxy]-N-(1-methylpiperidin-4-yl)benzamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 459.59

Molecular Weight (Monoisotopic): 459.2522

AlogP: 3.11

#Rotatable Bonds: 4

Polar Surface Area: 65.04

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.56

CX Basic pKa: 8.69

CX LogP: 2.58

CX LogD: 0.62

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.69

Np Likeness Score: -0.32

References

1. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S..  (2012)  Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.,  22  (1): [PMID:22153941] [10.1016/j.bmcl.2011.11.034]

2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data